The End Game: Laboratory Insiders on Your Side is a podcast by senior lab executives for senior lab executives. This podcast shares valuable industry knowledge, tips, and strategies that when applied and properly executed will help lab executives succeed, thrive, and ultimately become better prepared for their own End Game.
Listen to episodes
56 recent
August 27, 202610 min
Navigating Alzheimer's: Insights and Interventions
In this episode of the End Game Podcast, host Melissa Butterworth discusses her personal journey in the laboratory diagnostic space and delves into the complexities of Alzheimer's disease. She highlights the current state of treatments, including anti-amyloid therapies, and emphasizes the importance of early diagnosis. The conversation shifts to lifestyle interventions that can support cognitive health, such as exercise, nutrition, and social engagement. Finally, Melissa encourages proactive approaches to improve the quality of life for those affected by Alzheimer's, urging listeners to seek community support and professional guidance.
August 13, 20266 min
The Future of Alzheimer's Diagnosis: How Blood-Based Biomarkers Are Changing Care
The future of Alzheimer's diagnosis is here—and it's happening with a simple blood test. In this episode, we explore how blood-based biomarkers are transforming the detection and management of Alzheimer's disease. Learn how innovative tests measuring biomarkers like P-TAU217 are providing highly accurate, less invasive alternatives to traditional PET scans and cerebrospinal fluid testing, making earlier diagnosis more accessible than ever. We also discuss the critical role clinical laboratories play in implementing these advanced diagnostic technologies, the infrastructure required to support high-sensitivity testing, and how labs are helping monitor the effectiveness and safety of emerging Alzheimer's therapies. As personalized medicine continues to evolve, laboratory diagnostics are becoming an essential part of improving patient outcomes and supporting long-term disease management. In this episode, you'll learn: How blood-based biomarkers are changing Alzheimer's diagnosis Why P-TAU217 is emerging as a key diagnostic marker The shift from imaging to serum-based testing Laboratory challenges and opportunities in high-sensitivity diagnostics How blood tests are supporting personalized treatment monitoring for Alzheimer's patients Whether you're a laboratory professional, healthcare leader, or simply interested in the latest advancements in diagnostic medicine, this episode offers valuable insights into one of the fastest-growing areas of laboratory innovation.
July 30, 2026Episode 226 min
Lab Industry 2026: The Power of Integration
Melissa Butterworth shares her personal journey and introduces the topic of lab future and trends. She discusses the integration of labs, the role of AI and automation, the importance of data foundation, regulatory challenges, and the shift towards sustainability as a metric in the lab industry. Takeaways Integration is the key trend in the lab industry. Sustainability has become a mandatory KPI for labs in 2026. Chapters 00:00 Introduction and Personal Journey 01:22 Lab Future and Trends 01:52 AI and Automation in Labs 02:19 Data Foundation and AI Initiatives 03:17 Regulatory Tightrope 04:32 Sustainability as a Metric
July 16, 2026Episode 2110 min
Maximize Your Lab's Value: Timing and Preparation Tips
In this episode, Melissa Butterworth discusses the strategic timing for selling your laboratory, emphasizing preparation, market conditions, and personal readiness. Perfect for lab owners considering exit strategies, this episode offers actionable insights to maximize value.
November 12, 2025Episode 138 min
Empowering Your Health: The Rise of Direct-to-Consumer Testing
In this conversation, Melissa Butterworth discusses the rise of direct-to-consumer testing, emphasizing how it empowers patients to take control of their health. She likens the market to Netflix, highlighting its convenience and personalization.
October 1, 2025Episode 109 min
Navigating the Clinical Lab Landscape
In this episode, Melissa Butterworth discusses the current state and future of the clinical laboratory industry, highlighting its significance in medical decision-making, the types of labs, and the impact of technology and consolidation on the market.
May 14, 2025Episode 114 min
Unlocking Laboratory Value: The Advanced Strategic Partners Story
In this episode, Melissa Butterworth discusses the founding of Advanced Strategic Partners, highlighting her extensive experience in the laboratory industry and the unique differentiators of her firm. She elaborates on the services offered, including valuation and operational assessments, and emphasizes the importance of insider connections in maximizing laboratory value.
November 13, 2024Episode 731 min
Five Habits to 10x Your Sales Performance
In this episode of the End Game podcast, Melissa Butterworth shares the top five habits of the most successful salespeople, drawing from her personal experiences and insights from John Maxwell. She emphasizes the importance of self-improvement, goal setting, and creating a structured routine to achieve success in sales and life.
June 11, 2025Episode 37 min
Selling Smart: How Lab Owners Can Avoid Undervalued Offers
In this episode, Melissa Butterworth discusses the importance of not accepting direct offers for lab sales without going through a comprehensive six-step M&A process. She emphasizes the need for lab owners to evaluate their offers in the market to maximize their lab's value. Drawing from her personal experience as a lab owner, she shares insights on how competition can lead to better offers and encourages listeners to reach out for more information on the M&A process.
February 21, 2024Episode 424 min
Differences Between an Asset and Stock Transaction
I n this episode, Melissa Butterworth discusses the differences between asset and stock transactions in lab M&A deals and how they can affect valuation. She also explains the two types of buyers in the market: strategic buyers and non-strategic buyers. Strategic buyers are more likely to pay maximum value for a lab due to the synergies they can recognize between their entity and the one being sold. On the other hand, non-strategic buyers may pay based on a standard multiplier of adjusted EBITDA. Melissa emphasizes the importance of a competitive process in negotiating the price and achieving maximum valuation.
Is this your show?
Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.
